Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, September 27, 2016
Camargo Pharmaceutical Services has announced the addition of a former Food and Drug Administration medical device expert to their team to meet increasing demand from clients.
read more
Wednesday, November 27, 2013
Jim Beach, a veteran health care executive with broad
experience in operations, R&D, marketing and sales, has been named chief operating officer for
Camargo Pharmaceutical Services, a leading drug development organization specializing in the
505(b...
read more
Camargo Pharmaceutical Services announced it will acquire InSymbiosis, a Canadian drug development partner which improves how biopharma companies outsource R&D.
read more
Tuesday, February 18, 2014
Camargo Pharmaceutical Services’ Ready 4 Action
proprietary feasibility assessment enables drug developers — generic companies in particular
— to identify viable products to bring to market. Camargo will be exhibiting at the Generic
Pharmaceutical...
read more
Cambrex announced the acquisition of Q1 Scientific – a provider of environmentally-controlled cGMP stability storage services for the pharmaceutical, medical device and life science industries, strategically located in Waterford, Ireland.
read more
Tuesday, October 24, 2017
Cambrex announced the completion of an expansion to its large scale production capacity at its Iowa plant.
read more
Cambrex announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa.
read more
Tuesday, January 07, 2020
Cambrex has announced changes to its management team and Board of Directors.
read more
Wednesday, April 01, 2020
Cambrex announced Troy Player has been appointed as President, Early Stage Development and Testing (ESDT).
read more
Thursday, December 05, 2024
Cambrex, announced that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly's biotech collaborators.
read more
Cambrex Corporation has announced the completion and validation of a $50 million state-of-the-art production and warehousing expansion at its cGMP Charles City, Iowa site. The investment in capacity and capabilities was made in reflection of strong ...
read more
Thursday, January 19, 2023
Cambrex has completed its acquisition of Snapdragon Chemistry, a US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
read more
Friday, December 06, 2019
Cambrex announced the completion of its previously announced sale to an affiliate of the Permira funds.
read more
Wednesday, January 02, 2019
Cambrex has completed the acquisition of Avista Pharma Solutions, a contract development, manufacturing, and testing organization, from Ampersand Capital Partners.
read more
Thursday, September 13, 2018
Cambrex has completed the acquisition of Halo Pharma, a dosage form CDMO located in Whippany, New Jersey and Mirabel, Québec, Canada, for approximately $425 million.
read more